TG Therapeutics Faces Slowing Sales Growth for MS Drug Briumvi, Testing Investor Optimism
-
Briumvi, TG Therapeutics' MS drug, showed steady revenue growth in its first 3 quarters post-launch, but recent slowing growth hints at market saturation or increasing competition.
-
TG Therapeutics has a strong balance sheet with substantial cash reserves, but is still spending heavily on SG&A for Briumvi commercialization.
-
Revenue growth deceleration in Q4 and forecasted Q1 '24 caused a 25% stock price drop, indicating investor wariness about momentum.
-
Analyst maintains a "Hold" rating based on cautious optimism, warning investors to watch for risk factors like competitive threats.
-
Positives like nearing profitability and $240 million revenue estimate keep analyst rating at "Hold," but stock requires close monitoring.